MedTrace Logo

COVID19-Convalescent Plasma for Treating Patients With Active Symptomatic COVID 19 Infection (FALP-COVID)

NCT04384588 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-05-12

No results posted yet for this study

Summary

COVID-19 infection has spread worldwide causing several deaths in few months Convalescent Plasma from COVID 19 donors has shown huge activity in small series from Chinese patients and currently many centers from USA and the European Union are assessing its use looking to avoid mortality and prolonged hospitalizations COVID-19-related

Conditions

  • COVID-19 Infection
  • Cancer Patients
  • General Population

Interventions

BIOLOGICAL

Convalescent Plasma from COVID-19 donors

Patients that will participate in this clinical trial will be treated with Convalescent Plasma from COVID-19 donors regardless of the arm where they will be included

Sponsors & Collaborators

  • Confederación de la Producción y del Comercio (CPC)

    collaborator UNKNOWN

  • Bolsa de Santiago

    collaborator UNKNOWN

  • Fundacion Arturo Lopez Perez

    lead OTHER

Principal Investigators

  • Raimundo Gazitua, MD · Fundacion Arturo Lopez Perez

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-07
Primary Completion
2021-04-06
Completion
2021-04-06

Countries

  • Chile

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04384588 on ClinicalTrials.gov